IL-6 mediates the susceptibility of glycoprotein 130 hypermorphs to Toxoplasma gondii

Journal of Immunology

Volumn 187, Issue 1, 2011, Pages 350-360

  Silver, Jonathan S ^a   Stumhofer, Jason S ^a   Passos, Sara ^a,c   Ernst, Matthias ^b   Hunter, Christopher A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^c Hospital Universitario   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN GP 130; INTERLEUKIN 12; INTERLEUKIN 6; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; GENE MUTATION; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; INFECTION SENSITIVITY; MOUSE; NONHUMAN; PARASITE LOAD; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TOXOPLASMA GONDII;

ANIMALS; CELLS, CULTURED; CYTOKINE RECEPTOR GP130; GENETIC PREDISPOSITION TO DISEASE; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, KNOCKOUT; SIGNAL TRANSDUCTION; TOXOPLASMA; TOXOPLASMOSIS;

EID: 79960388683     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1004144     Document Type: Article

References (65)

1. Taga, T., and T. Kishimoto. 1997. Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 15: 797-819.
2. O'Shea, J. J., M. Gadina, and R. D. Schreiber. 2002. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109(Suppl.): S121-S131.
3. O'Shea, J. J., and P. J. Murray. 2008. Cytokine signaling modules in inflammatory responses. Immunity 28: 477-487.
4. De Souza, D., L. J. Fabri, A. Nash, D. J. Hilton, N. A. Nicola, and M. Baca. 2002. SH2 domains from suppressor of cytokine signaling-3 and protein tyrosine phosphatase SHP-2 have similar binding specificities. Biochemistry 41: 9229-9236. (Pubitemid 34787281)
5. Nicholson, S. E., D. De Souza, L. J. Fabri, J. Corbin, T. A. Willson, J. G. Zhang, A. Silva, M. Asimakis, A. Farley, A. D. Nash, et al. 2000. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc. Natl. Acad. Sci. USA 97: 6493-6498.
6. Schmitz, J., M. Weissenbach, S. Haan, P. C. Heinrich, and F. Schaper. 2000. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J. Biol. Chem. 275: 12848-12856.
7. Babon, J. J., J. K. Sabo, A. Soetopo, S. Yao, M. F. Bailey, J. G. Zhang, N. A. Nicola, and R. S. Norton. 2008. The SOCS box domain of SOCS3: structure and interaction with the elonginBC-cullin5 ubiquitin ligase. J. Mol. Biol. 381: 928-940.
8. Tebbutt, N. C., A. S. Giraud, M. Inglese, B. Jenkins, P. Waring, F. J. Clay, S. Malki, B. M. Alderman, D. Grail, F. Hollande, et al. 2002. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat. Med. 8: 1089-1097.
9. Ohtani, T., K. Ishihara, T. Atsumi, K. Nishida, Y. Kaneko, T. Miyata, S. Itoh, M. Narimatsu, H. Maeda, T. Fukada, et al. 2000. Dissection of signaling cascades through gp130 in vivo: reciprocal roles for STAT3- and SHP2-mediated signals in immune responses. Immunity 12: 95-105. (Pubitemid 30069218)
10. Jenkins, B. J., A. W. Roberts, C. J. Greenhill, M. Najdovska, T. Lundgren-May, L. Robb, D. Grail, and M. Ernst. 2007. Pathologic consequences of STAT3 hyperactivation by IL-6 and IL-11 during hematopoiesis and lymphopoiesis. Blood 109: 2380-2388. (Pubitemid 46425878)
11. Jenkins, B. J., D. Grail, T. Nheu, M. Najdovska, B. Wang, P. Waring, M. Inglese, R. M. McLoughlin, S. A. Jones, N. Topley, et al. 2005. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-β signaling. Nat. Med. 11: 845-852.
12. Jenkins, B. J., A. W. Roberts, M. Najdovska, D. Grail, and M. Ernst. 2005. The threshold of gp130-dependent STAT3 signaling is critical for normal regulation of hematopoiesis. Blood 105: 3512-3520. (Pubitemid 40628193)
13. Ernst, M., M. Najdovska, D. Grail, T. Lundgren-May, M. Buchert, H. Tye, V. B. Matthews, J. Armes, P. S. Bhathal, N. R. Hughes, et al. 2008. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J. Clin. Invest. 118: 1727-1738.
14. Atsumi, T., K. Ishihara, D. Kamimura, H. Ikushima, T. Ohtani, S. Hirota, H. Kobayashi, S. J. Park, Y. Saeki, Y. Kitamura, and T. Hirano. 2002. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J. Exp. Med. 196: 979-990.
15. + T cells. J. Exp. Med. 203: 1459-1470.
16. Rebouissou, S., M. Amessou, G. Couchy, K. Poussin, S. Imbeaud, C. Pilati, T. Izard, C. Balabaud, P. Bioulac-Sage, and J. Zucman-Rossi. 2009. Frequent inframe somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457: 200-204.
17. Nowell, M. A., A. S. Williams, S. A. Carty, J. Scheller, A. J. Hayes, G. W. Jones, P. J. Richards, S. Slinn, M. Ernst, B. J. Jenkins, et al. 2009. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J. Immunol. 182: 613-622.
18. Nishimoto, N., K. Yoshizaki, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi, J. Hashimoto, J. Azuma, and T. Kishimoto. 2004. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 50: 1761-1769. (Pubitemid 38725087)
19. Hunter, C. A., and J. S. Remington. 1994. Immunopathogenesis of toxoplasmic encephalitis. J. Infect. Dis. 170: 1057-1067.
20. Sher, A., E. Y. Denkers, and R. T. Gazzinelli. 1995. Induction and regulation of host cell-mediated immunity by Toxoplasma gondii. Ciba Found. Symp. 195: 95-104, discussion 104-109.
21. Sher, A., C. Collazzo, C. Scanga, D. Jankovic, G. Yap, and J. Aliberti. 2003. Induction and regulation of IL-12-dependent host resistance to Toxoplasma gondii. Immunol. Res. 27: 521-528.
22. Denkers, E. Y., and R. T. Gazzinelli. 1998. Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin. Microbiol. Rev. 11: 569-588.
23. Suzuki, Y., F. K. Conley, and J. S. Remington. 1989. Importance of endogenous IFN-γ for prevention of toxoplasmic encephalitis in mice. J. Immunol. 143: 2045-2050.
24. Suzuki, Y., S. Rani, O. Liesenfeld, T. Kojima, S. Lim, T. A. Nguyen, S. A. Dalrymple, R. Murray, and J. S. Remington. 1997. Impaired resistance to the development of toxoplasmic encephalitis in interleukin-6-deficient mice. Infect. Immun. 65: 2339-2345.
25. Jebbari, H., C. W. Roberts, D. J. Ferguson, H. Bluethmann, and J. Alexander. 1998. A protective role for IL-6 during early infection with Toxoplasma gondii. Parasite Immunol. 20: 231-239. (Pubitemid 28255396)
26. Drögemüller, K., U. Helmuth, A. Brunn, M. Sakowicz-Burkiewicz, D. H. Gutmann, W. Mueller, M. Deckert, and D. Schlüter. 2008. Astrocyte gp130 expression is critical for the control of Toxoplasma encephalitis. J. Immunol. 181: 2683-2693.
27. Villarino, A., L. Hibbert, L. Lieberman, E. Wilson, T. Mak, H. Yoshida, R. A. Kastelein, C. Saris, and C. A. Hunter. 2003. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 19: 645-655.
28. Stumhofer, J. S., A. Laurence, E. H. Wilson, E. Huang, C. M. Tato, L. M. Johnson, A. V. Villarino, Q. Huang, A. Yoshimura, D. Sehy, et al. 2006. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat. Immunol. 7: 937-945.
29. Silver, J. S., and C. A. Hunter. 2010. gp130 at the nexus of inflammation, autoimmunity, and cancer. J. Leukoc. Biol. 88: 1145-1156.
30. Wilson, E. H., U. Wille-Reece, F. Dzierszinski, and C. A. Hunter. 2005. A critical role for IL-10 in limiting inflammation during toxoplasmic encephalitis. J. Neuroimmunol. 165: 63-74.
31. Stumhofer, J. S., J. S. Silver, A. Laurence, P. M. Porrett, T. H. Harris, L. A. Turka, M. Ernst, C. J. Saris, J. J. O'Shea, and C. A. Hunter. 2007. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat. Immunol. 8: 1363-1371.
32. Taylor, G. A., C. G. Feng, and A. Sher. 2004. p47 GTPases: regulators of immunity to intracellular pathogens. Nat. Rev. Immunol. 4: 100-109.
33. Collazo, C. M., G. S. Yap, G. D. Sempowski, K. C. Lusby, L. Tessarollo, G. F. Woude, A. Sher, and G. A. Taylor. 2001. Inactivation of LRG-47 and IRG-47 reveals a family of interferon g-inducible genes with essential, pathogen-specific roles in resistance to infection. J. Exp. Med. 194: 181-188.
34. Taylor, G. A., C. M. Collazo, G. S. Yap, K. Nguyen, T. A. Gregorio, L. S. Taylor, B. Eagleson, L. Secrest, E. A. Southon, S.W. Reid, et al. 2000. Pathogen-specific loss of host resistance in mice lacking the IFN-γ-inducible gene IGTP. Proc. Natl. Acad. Sci. USA 97: 751-755.
35. + cells as effectors of IFN-γ dependent immunity to Toxoplasma gondii in MHC class I-deficient mice. J. Exp. Med. 178: 1465-1472.
36. Hunter, C. A., C. S. Subauste, V. H. Van Cleave, and J. S. Remington. 1994. Production of γ interferon by natural killer cells from Toxoplasma gondiiinfected SCID mice: regulation by interleukin-10, interleukin-12, and tumor necrosis factor a. Infect. Immun. 62: 2818-2824.
37. Passos, S. T., J. S. Silver, A. C. O'Hara, D. Sehy, J. S. Stumhofer, and C. A. Hunter. 2010. IL-6 promotes NK cell production of IL-17 during toxoplasmosis. J. Immunol. 184: 1776-1783.
38. Khan, I. A., T. Matsuura, and L. H. Kasper. 1994. Interleukin-12 enhances murine survival against acute toxoplasmosis. Infect. Immun. 62: 1639-1642.
39. Sher, A., I. P. Oswald, S. Hieny, and R. T. Gazzinelli. 1993. Toxoplasma gondii induces a T-independent IFN-g response in natural killer cells that requires both adherent accessory cells and tumor necrosis factor-a. J. Immunol. 150: 3982-3989.
40. + T cells and accompanied by overproduction of IL-12, IFN-γ and TNF-α. J. Immunol. 157: 798-805.
41. D'Andrea, A., M. Aste-Amezaga, N. M. Valiante, X. Ma, M. Kubin, and G. Trinchieri. 1993. Interleukin 10 (IL-10) inhibits human lymphocyte interferon γ-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med. 178: 1041-1048.
42. Awasthi, A., Y. Carrier, J. P. Peron, E. Bettelli, M. Kamanaka, R. A. Flavell, V. K. Kuchroo, M. Oukka, and H. L. Weiner. 2007. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat. Immunol. 8: 1380-1389.
43. Fitzgerald, D. C., G. X. Zhang, M. El-Behi, Z. Fonseca-Kelly, H. Li, S. Yu, C. J. Saris, B. Gran, B. Ciric, and A. Rostami. 2007. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat. Immunol. 8: 1372-1379.
44. McGeachy, M. J., K. S. Bak-Jensen, Y. Chen, C. M. Tato, W. Blumenschein, T. McClanahan, and D. J. Cua. 2007. TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat. Immunol. 8: 1390-1397.
45. + cells in nonhealing Leishmania major infection. J. Immunol. 183: 4619-4627.
46. +Foxp3-Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. J. Exp. Med. 204: 273-283.
47. Croker, B. A., D. L. Krebs, J. G. Zhang, S. Wormald, T. A. Willson, E. G. Stanley, L. Robb, C. J. Greenhalgh, I. Förster, B. E. Clausen, et al. 2003. SOCS3 negatively regulates IL-6 signaling in vivo. Nat. Immunol. 4: 540-545.
48. Yasukawa, H., M. Ohishi, H. Mori, M. Murakami, T. Chinen, D. Aki, T. Hanada, K. Takeda, S. Akira, M. Hoshijima, et al. 2003. IL-6 induces an antiinflammatory response in the absence of SOCS3 in macrophages. Nat. Immunol. 4: 551-556.
49. Lang, R., A. L. Pauleau, E. Parganas, Y. Takahashi, J. Mages, J. N. Ihle, R. Rutschman, and P. J. Murray. 2003. SOCS3 regulates the plasticity of gp130 signaling. Nat. Immunol. 4: 546-550.
50. Gazzinelli, R. T., S. Hieny, T. A. Wynn, S. Wolf, and A. Sher. 1993. Interleukin 12 is required for the T-lymphocyte-independent induction of interferon γ by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc. Natl. Acad. Sci. USA 90: 6115-6119.
51. Middleton, M. K., A. M. Zukas, T. Rubinstein, M. Kinder, E. H. Wilson, P. Zhu, I. A. Blair, C. A. Hunter, and E. Puré. 2009. 12/15-lipoxygenase- dependent myeloid production of interleukin-12 is essential for resistance to chronic toxoplasmosis. Infect. Immun. 77: 5690-5700.
52. Saraiva, M., and A. O'Garra. 2010. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 10: 170-181.
53. Stumhofer, J. S., and C. A. Hunter. 2008. Advances in understanding the antiinflammatory properties of IL-27. Immunol. Lett. 117: 123-130.
54. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3: 133-146.
55. Yu, C. R., R. M. Mahdi, S. Ebong, B. P. Vistica, I. Gery, and C. E. Egwuagu. 2003. Suppressor of cytokine signaling 3 regulates proliferation and activation of T-helper cells. J. Biol. Chem. 278: 29752-29759.
56. Ernst, M., and B. J. Jenkins. 2004. Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet. 20: 23-32.
57. El Kasmi, K. C., J. Holst, M. Coffre, L. Mielke, A. de Pauw, N. Lhocine, A. M. Smith, R. Rutschman, D. Kaushal, Y. Shen, et al. 2006. General nature of the STAT3-activated anti-inflammatory response. J. Immunol. 177: 7880-7888. (Pubitemid 44846303)
58. Rose-John, S., J. Scheller, G. Elson, and S. A. Jones. 2006. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J. Leukoc. Biol. 80: 227-236.
59. Dodge, I. L., M. W. Carr, M. Cernadas, and M. B. Brenner. 2003. IL-6 production by pulmonary dendritic cells impedes Th1 immune responses. J. Immunol. 170: 4457-4464.
60. Beaman, M. H., C. A. Hunter, and J. S. Remington. 1994. Enhancement of intracellular replication of Toxoplasma gondii by IL-6. Interactions with IFN-γ and TNF-α. J. Immunol. 153: 4583-4587.
61. Diehl, S., J. Anguita, A. Hoffmeyer, T. Zapton, J. N. Ihle, E. Fikrig, and M. Rincón. 2000. Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1. Immunity 13: 805-815. (Pubitemid 32041803)
62. Nagabhushanam, V., A. Solache, L. M. Ting, C. J. Escaron, J. Y. Zhang, and J. D. Ernst. 2003. Innate inhibition of adaptive immunity: Mycobacterium tuberculosis-induced IL-6 inhibits macrophage responses to IFN-γ. J. Immunol. 171: 4750-4757.
63. Bermudez, L. E., M. Wu, M. Petrofsky, and L. S. Young. 1992. Interleukin-6 antagonizes tumor necrosis factor-mediated mycobacteriostatic and mycobactericidal activities in macrophages. Infect. Immun. 60: 4245-4252.
64. Xing, Z., J. Gauldie, G. Cox, H. Baumann, M. Jordana, X. F. Lei, and M. K. Achong. 1998. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J. Clin. Invest. 101: 311-320.
65. Grivennikov, S. I., F. R. Greten, and M. Karin. 2010. Immunity, inflammation, and cancer. Cell 140: 883-899.